Emostasi e Trombosi, S.I. di (2026) “PO49 | PROPHYLACTIC ANTICOAGULATION DECISIONS IN HIGH-RISK PATIENTS RECEIVING CANCER-DIRECTED THERAPY: ANALYSIS OF THE VERMONT METHOD: J. Barker1, K. Libby1, C. Holmes2, K. Martin2 | 1University of Vermont Health System; 2Department of Medicine, University of Vermont, Burlington, VT, USA”, Bleeding, Thrombosis and Vascular Biology, 5(s1). doi:10.4081/btvb.2026.541.